Table V.
Baseline characteristics, RCC28, PC28, ANC29 and RDI-AZA1 according to the risk group defined by KCSS in the training set.
| Parameter | Good-risk group (n=68) | Intermediate-risk group (n=63) | Poor-risk group (n=12) | P-value |
|---|---|---|---|---|
| Age, years | 76 (56–94) | 76 (52–90) | 68 (52–84) | 0.079 |
| Male/Female, n (%) | 45 (66.2)/23 (33.8) | 47 (74.6)/16 (25.4) | 6 (50.0)/6 (50.0) | 0.206 |
| Hemoglobin level, g/dl | 8.1 (5.7–13.0) | 7.7 (3.5–11.2) | 7.3 (6.1–10.0) | 0.174 |
| Platelet counts, ×109/l | 88.5 (17.0–1139.0) | 46.0 (3.0–470.0) | 23.5 (2.0–270.0) | <0.001 |
| WBC, ×109/l | 2.6 (0.8–19.0) | 2.4 (1.0–24.4) | 2.4 (0.8–22.1) | 0.888 |
| ANC, ×109/l | 1.1 (0.0–13.1) | 1.0 (0.1–10.6) | 0.8 (0.1–19.6) | 0.703 |
| Blast in bone marrow, % | 7.8 (0.4–19.4) | 6.8 (0.0–19.8) | 8.0 (0.3–18.4) | 0.959 |
| Cytogenetic risk according to IPSS-R, n (%) | <0.001 | |||
| Very good | 2 (2.9) | 0 (0.0) | 0 (0.0) | |
| Good | 25 (36.8) | 9 (14.3) | 0 (0.0) | |
| Intermediate | 27 (39.7) | 6 (9.5) | 0 (0.0) | |
| Poor | 14 (20.6) | 1 (1.6) | 0 (0.0) | |
| Very poor | 0 (0.0) | 47 (74.6) | 12 (100.0) | |
| RCC28, unit | 2 (0–10) | 4 (0–24) | 8 (2–30) | <0.001 |
| PC28, unit | 0 (0–30) | 10 (0–170) | 60 (40–120) | <0.001 |
| ANC29, ×109/l | 0.7 (0.0–9.0) | 0.4 (0.0–9.3) | 0.2 (0.1–5.6) | 0.003 |
| RDI-AZA1, %, median (IQR) | 90 (69–98) | 89 (63–96) | 92 (66–96) | 0.553 |
Data presented as median (range) unless otherwise shown. KCSS, Kyoto Conditional Survival Scoring System; RCC, red cell concentrates; PC, platelet concentrate; ANC, absolute neutrophil counts; RDI-AZA1, relative dose intensity in the first cycle of azacitidine treatment.